CVRx, Inc. (CVRX)
NASDAQ (NGS) NASDAQ (NGS) Primary Summary
CVRx Secures Devoted Health Coverage for Barostim Therapy
CVRX secures Devoted Health Medicare Advantage coverage for Barostim, expanding reimbursement access to about 466,000 members across 29 states.
CVRx Eyes Barostim Growth as Coverage Gains and BENEFIT-HF Trial Launches
CVRx NASDAQ: CVRX outlined its efforts to expand adoption of its Barostim therapy for heart failure patients, emphasizing sales-force execution, payer coverage progress and a large post-market clinical trial during Canaccord Genuity's 46th Annual Growth Conference.
CVRx, Inc. (CVRX) Q2 2026 Earnings Call Transcript
CVRx, Inc. (CVRX) Q2 2026 Earnings Call Transcript
CVRx, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 40 | $378 | $113.6 | -$264.4 | -69.95% |
 Marc Larkins Johnson & Johnson | 4.02M | $67.59M | $11.39M | -$56.2M | -83.15% |
 Point72 Asset Management LP Point72 Asset Management LP | 26,773 | $137,613 | $82,460.84 | -$55,152.16 | -40.08% |
 Joseph Castro Nuveen LLC | 49,546 | $444,328.66 | $140,710.64 | -$303,618.02 | -68.33% |
 Bobby Adusumilli SJS Investment Consulting Inc. | 3 | $28.38 | $8.51 | -$19.87 | -70.01% |
CVRx, Inc. (CVRX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has CVRx, Inc. ever had a stock split?
CVRx, Inc. Profile
| Health Care Equipment & Supplies Industry | Healthcare Sector | Kevin Hykes CEO | NASDAQ (NGS) Exchange | 126638105 CUSIP |
| US Country | 223 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
CVRx, Inc. is a commercial-stage medical device company with a primary focus on the development, manufacturing, and commercialization of neuromodulation solutions aimed at treating cardiovascular diseases. Incorporated in the year 2000 and based in Minneapolis, Minnesota, CVRx has positioned itself at the forefront of the medical device industry by targeting a significant need within the cardiovascular disease treatment spectrum. Through its innovative approach, the company seeks to improve the quality of life for patients suffering from severe cardiovascular conditions by leveraging the potential of neuromodulation therapies. CVRx not only serves patients within the United States but also reaches a global audience, including Germany, through a combination of direct sales force, sales agents, and independent distributors, underscoring its commitment to addressing heart failure on a worldwide scale.
Products and Services
- Barostim
Barostim stands out as CVRx, Inc.’s flagship neuromodulation device, designed specifically to offer symptom improvement for patients dealing with heart failure with reduced ejection fraction, commonly referred to as systolic heart failure. By leveraging the advanced mechanism of neuromodulation, Barostim aims at enhancing the quality of life for those afflicted by this debilitating condition, marking a significant milestone in the treatment of heart failure. Its indication for this particular group of patients highlights the company's dedication to filling a critical gap in cardiovascular disease management through innovative technology.
